еÃÀû

DSPE-PEG2000-MAL£º¸³ÄÜin vivo CAR-TµÝË͵ÄÐÂ×¥ÊÖ

2025-11-04

×ÖºÅ

¡¡¡¡CAR-TÁÆ·¨ÊÇÈËÀàÔÚÉúÎïÒ½Ò©ÁìÓò¼ÌС·Ö×Ó¡¢´ó·Ö×ÓÒԺ󣬣¬£¬ÔÚϸ°û²ãÃæÈ¡µÃµÄÓÖÒ»´Î¸ïÃüÐÔÍ»ÆÆ¡£¡£¡£¡£ÌåÍâCAR-T(ex vivo CAR-T)ÒÑÔÚBϸ°û°×Ѫ²¡ºÍÁÜ°ÍÁö´´ÏÂÁËѤÀõÄÀï³Ì±®£¬£¬£¬µ«ÆäÖØ´óµÄÖÆÔìÀú³Ì¡¢¸ß°ºµÄÓöȼ°¶¾ÐԵȾÖÏÞ³ÉΪÁËÕâÏîÊÖÒÕ´óÃæ»ýÆÕ¼°µÄÆ¿¾±ËùÔÚ¡£¡£¡£¡£¶øÌåÄÚCART(in vivo CAR-T)ÔòÒÔÇ㸲ÐÔµÄÊÖÒÕ£¬£¬£¬Í¨¹ýÌØÊâÔØÌ彫CAR»ùÒòÖ±½ÓËÍÈëÌåÄÚ£¬£¬£¬Ìø¹ý·±ËöµÄÌåÍâ°ì·¨£¬£¬£¬Ö±½ÓÔÚ»¼ÕßÌåÄÚÍê³É¶ÔTϸ°ûµÄ“×°±¸Éý¼¶”£¬£¬£¬³ÉΪÏÂÒ»´úϸ°ûÃâÒßÖÎÁƵÄÆƾֵã¡£¡£¡£¡£

¡¡¡¡2025Äê6ÔÂ11ÈÕ£¬£¬£¬ÔËÓÃLNPΪÖ÷ÒªµÝËÍÔØÌåµÄin vivo CAR-TÁÆ·¨¹«Ë¾CapstanÐû²¼£¬£¬£¬ÆäÒÔרÓÐÊÖÒÕtLNP(ÌåÄÚ°ÐÏòÖ¬ÖÊÄÉÃ׿ÅÁ£)ΪÔØÌåµÄin vivo CAR-Tϸ°ûÁÆ·¨CPTX2309Õýʽ×îÏÈ¢ñÆÚÁÙ´²ÊÔÑ飬£¬£¬ÓÃÓÚÖÎÁÆBϸ°û½éµ¼µÄ×ÔÉíÃâÒß¼²²¡1¡£¡£¡£¡£Ëæºó£¬£¬£¬2025Äê6ÔÂ30ÈÕ£¬£¬£¬°¬²®Î¬ÓëCapstanÐû¹«¸æ¿¢×îÖÕЭÒ飬£¬£¬°¬²®Î¬½«ÒÔ21ÒÚÃÀÔªµÄ¼ÛÇ®ÊÕ¹ºCapstan£¬£¬£¬´Ë´ÎÊÕ¹ºº­¸ÇÆä¸Õ½øÈë¢ñÆÚÁÙ´²ÊÔÑéµÄCPTX23092¡£¡£¡£¡£Í¬Ê±£¬£¬£¬°¬²®Î¬»¹½«»ñµÃCapstanµÄtLNPƽ̨ÊÖÒÕ£¬£¬£¬¸ÃÊÖÒÕÖ¼ÔÚµÝËÍRNAÓÐÓÃÔغÉ(ÈçmRNA)£¬£¬£¬Äܹ»ÔÚÌåÄÚ¶ÔÌض¨Ï¸°ûÀàÐ;ÙÐй¤³ÌˢС£¡£¡£¡£

¡¡¡¡ÄÉÃ×ÊÖÒյķÉËÙÉú³¤ÎªÒ©ÎïµÝËÍϵͳ´øÀ´Á˸ïÃüÐÔµÄÍ»ÆÆ¡£¡£¡£¡£ÒÔCapstanµÄÊÖÒÕƽ̨ΪÀý£¬£¬£¬ÔÚÖƱ¸LNPʱ»ìÈëÒÔÂíÀ´õ£ÑÇ°·»ùÍÅ(-Maleimide£¬£¬£¬MAL)µÄPEGÖ¬£¬£¬£¬´ýLNPÖƱ¸Íê³Éºó£¬£¬£¬ÔÙ½«´øÓÐÛÏ»ù(-SH)µÄ¿¹Ìåͨ¹ý·õÓýµÄ·½·¨Å¼ÁªÔÚº¬ÓÐMAL»ùÍŵÄPEGÖ¬ÉÏ£¬£¬£¬¼´¿É¸¶ÓëLNPϵͳ“×Ô¶¯°ÐÏò”µÄÄÜÁ¦¡£¡£¡£¡£

¡¡¡¡DSPE-PEG2000-MAL(1,2-¶þÓ²Ö¬õ£-sn-¸ÊÓÍ-3-Á×ËáÒÒ´¼°·-¾ÛÒÒ¶þ´¼2000-ÂíÀ´õ£ÑÇ°·)×÷ΪһÖÖÉè¼Æ¾«ÇɵĹ¦Ð§»¯Á×Ö¬-PEGÑÜÉúÎ£¬£¬ÒѳÉΪ¹¹½¨ÏȽøÄ˽×ÔØÌåµÄÖ÷ÒªÁ¢ÒìÖÊÁÏÖ®Ò»¡£¡£¡£¡£ÆäÆæÒìµÄ·Ö×ӽṹ¸¶ÓëÁËÔØÌ峤ѭ»·¡¢×Ô¶¯°ÐÏò¼°¶à¹¦Ð§¼¯³É»¯µÄÄÜÁ¦£¬£¬£¬ÔÚ°ÐÏòÖÎÁÆ¡¢·Ö×ÓÓ°ÏñºÍÃâÒßÁÆ·¨µÈÁìÓòÕ¹ÏÖ³öÖØ´óµÄÓ¦ÓÃDZÁ¦¡£¡£¡£¡£

¡¡¡¡·Ö×ӽṹÓëÀí»¯ÌØÕ÷

¡¡¡¡DSPE-PEG2000-MALµÄ·Ö×ÓÁ¿Ô¼Îª2805–3000Da£¬£¬£¬Ö÷Òª°üÀ¨Èý¸ö¹¦Ð§Ã÷È·µÄÄ£¿£¿£¿é£º

¡¡¡¡DSPE(1,2-Distearoyl-sn-glycero-3-phosphoethanolamine)Êèˮ궨»ùÍÅ£º×÷ΪÁ½Ç×ÐÔ·Ö×ÓµÄÊèˮβ²¿£¬£¬£¬DSPEº¬ÓÐÁ½ÌõC18±¥ºÍÖ¬·¾ËáÁ´£¬£¬£¬Æä½á¹¹Óëϸ°ûĤÁ×֬˫·Ö×Ó²ã¾ßÓи߶ÈÇ׺ÍÐÔ£¬£¬£¬Äܹ»Îȹ̵ØǶÈëÖ¬ÖÊÌåĤ»ò×é³É½ºÊøµÄÊèË®Äںˣ¬£¬£¬ÎªÕû¸ö·Ö×ÓÌṩÀο¿µÄ궨×÷Óᣡ£¡£¡£

¡¡¡¡PEG2000(Polyethyleneglycol)Ç×Ë®Á´¶Î£º·Ö×ÓÁ¿Ô¼Îª2000DaµÄ¾ÛÒÒ¶þ´¼Á´×é³ÉÁË·Ö×ÓµÄÇ×Ë®¹Ú²ã¡£¡£¡£¡£ÔÚÐÄÀíÇéÐÎÖУ¬£¬£¬PEGÁ´Í¨¹ý¿Õ¼äλ×èЧӦºÍË®ÏàÖúÓ㬣¬£¬ÔÚÄ˽×ÔØÌåÍâòÐγÉÒ»²ãÖÂÃܵēˮ»¯ÔÆ”£¬£¬£¬ÓÐÓÃïÔ̭Ѫ½¬ÂÑ°×µÄÎü¸½£¬£¬£¬´Ó¶ø¹æ±ÜÍø×´ÄÚƤϵͳµÄ¿ìËÙɨ³ý¡£¡£¡£¡£ÕâÒ»ÌØÕ÷£¬£¬£¬¼´“ÒþÐÎЧӦ”(Stealth®effect)£¬£¬£¬ÊÇÑÓÉìÔØÌåÌåÄÚÑ­»·°ëË¥ÆÚµÄÒªº¦¡£¡£¡£¡£

¡¡¡¡MAL(Maleimide)»îÐÔ×îºó»ùÍÅ£ºÂíÀ´õ£ÑÇ°·»ùÍÅÊÇ·Ö×ӵķ´Ó¦»îÐÔÖÐÐÄ¡£¡£¡£¡£ËüÄÜÔÚpH6.5-7.2µÄÌõ¼þÏ£¬£¬£¬ÓëÛÏ»ù(-SH£¬£¬£¬Áò´¼)±¬·¢¸ßЧ¡¢ÌØÒìÐÔµÄÂõ¿Ë¶û¼Ó³É·´Ó¦£¬£¬£¬ÐγÉÎȹ̵ÄÁòÃѹ²¼Û¼ü¡£¡£¡£¡£ÕâÒ»»¯Ñ§Ñ¡ÔñÐÔʹÆä³ÉΪÅþÁ¬º¬°ëë×°±Ëá²Ð»ùµÄ°ÐÏòÅäÌå(È翹Ìå¡¢¶àëÄ¡¢ÊÊÅäÌå)µÄÀíÏë“»¯Ñ§×¥ÊÖ”¡£¡£¡£¡£

       

ÏîÄ¿ ÐÎò
Íâ¹Û °×É«»òÀà°×É«À¯×´¹ÌÌå
ÏûÈÚÐÔ ¿ÉÔÚDMSO¡¢ÒÒ´¼¡¢ÎÂË®ÖÐÊèÉ¢»òÏûÈÚ
pHÎȹÌÐÔ pH 6.5-7.2½ÏÎȹ̣¨×èÖ¹MaleimideË®½â£©
Ó¦Óà ֬ÖÊÌåÐÞÊΡ¢ÉúÎïżÁª¡¢°ÐÏòµÝË͵È

       ÔÚʹÓÃDSPE-PEG2000-MALµÄµÝËÍϵͳÖУ¬£¬£¬DSPE¶Ë²åÈëÁ×֬˫·Ö×Ӳ㣬£¬£¬PEGÁ´ÑÓÉìÖÁÍⲿˮÏ࣬£¬£¬ÏÔÖøÌáÉýÁËϵͳµÄÎȹÌÐÔºÍÌåÄÚÑ­»·¶¯Á¦Ñ§¡£¡£¡£¡£ÀýÈ磬£¬£¬¾­PEGÐÞÊεÄÖ¬ÖÊÌå(ÈçDoxil®)°ëË¥ÆÚ¿É´ÓÊýСʱÑÓÉìÖÁÔ¼55Сʱ£¬£¬£¬²¢½èÖúÔöÇ¿Éø͸ÖÍÁôЧӦÔÚÖ×Áö²¿Î»ÊµÏÖ±»¶¯¸»¼¯3¡£¡£¡£¡£¶øMAL»ùÍÅÄÜÓ뺬ÛÏ»ù(-SH)·Ö×Ó¶¨ÏòżÁªµÄÌØÕ÷£¬£¬£¬¸¶ÓëÆä“×Ô¶¯°ÐÏò”µÄÄÜÁ¦¡£¡£¡£¡£ÔÚ½ºÊøϵͳÖУ¬£¬£¬DSPE-PEG2000-MALÒ²¿É×Ô×é×°ÐγɺË-¿Ç½á¹¹£¬£¬£¬ÊèË®µÄDSPEÄÚºËÓÃÓÚÔöÈÜ×Ïɼ´¼µÈÄÑÈÜÐÔ»¯ÁÆÒ©Î£¬£¬¶øPEGÍâ¿ÇºÍMAL¹¦Ð§»¯ÍâòÔòͬÑùÌṩÎȹÌÐÔºÍ×Ô¶¯°ÐÏòµÄDZÁ¦£¬£¬£¬ÍØÕ¹mRNAÒ©ÎïµÄÓ¦ÓùæÄ££¬£¬£¬ÊµÏÖ¸ü¾«×¼µÄϸ°ûÀàÐÍÌØÒìÐÔµÝËÍ¡£¡£¡£¡£

¡¡¡¡DSPE-PEG2000-MALÒÀ¸½Æä“궨-ÒþÐÎ-ÅþÁ¬”ÈýλһÌåµÄ·Ö×ÓÉè¼Æ£¬£¬£¬ÒѳÉΪ¾«×¼Ò©ÎïµÝËÍÁìÓò²»¿É»òȱµÄ¹¦Ð§ÖÊÁÏ¡£¡£¡£¡£Ëü²»µ«½â¾öÁËÄ˽×ÔØÌåÔÚÌåÄÚµÄÎȹÌÐԺͳ¤Ñ­»·ÎÊÌ⣬£¬£¬¸üÖ÷ÒªµÄÊÇ£¬£¬£¬Í¨¹ýÆä¸ß¶ÈÌØÒìÐԵĻ¯Ñ§Å¼ÁªÄÜÁ¦£¬£¬£¬ÊµÏÖÁ˶ÔÄ˽×ÔØÌåµÄÍâò¹¦Ð§»¯£¬£¬£¬´Ó¶ø¸¶ÓëÆä×Ô¶¯°ÐÏò¡¢ÖÇÄÜÏìÓ¦ºÍÕïÁÆÒ»Ì廯µÈ¸ß¼¶¹¦Ð§¡£¡£¡£¡£Ëæ×ŶÔÃâÒßÉúÎïѧ»úÖƵÄÉîÈë̽Ë÷£¬£¬£¬DSPE-PEG2000-MAL¼°ÆäÑÜÉúÎｫ¼ÌÐø×÷Ϊ¹¹½¨Öش󡢸ßЧ¡¢ÖÇÄÜÄÉÃ×Ò©ÎïϵͳµÄÖ÷Òª»ùʯ֮һ£¬£¬£¬Îª¹¥¿ËÖØ´ó¼²²¡ÖÎÁÆÖеÄÖÖÖÖÌôÕ½ÌṩǿÓÐÁ¦µÄÊÖÒÕÖ§³Ö£¬£¬£¬Íƶ¯¾«×¼Ò½ÁÆÂõÏòеĸ߶È¡£¡£¡£¡£

¡¡¡¡×÷ΪרעÓÚÒ©ÎïµÝËÍÊÖÒÕµÄÁ¢ÒìÐÍÆóÒµ£¬£¬£¬ÐµÃÀû¿Æ¼¼³Ð¼Ì“ÒÔÖÊÁÏÁ¢ÒìÒýÁìÉúÎïÒ½Ò©Á¢Ò쓵Ä×ÚÖ¼£¬£¬£¬ÒÀÍÐ×ÔÉíÔÚÒ©ÎïµÝËÍÁìÓòµÄÖÕÄê»ýÀÛÓëÁ¢ÒìÓÅÊÆ£¬£¬£¬¿ÉΪÄúÌṩÇкÏÑз¢¼°ÖÐÍâÉ걨ÐèÇóµÄDSPE-PEG2000-MAL²úÆ·£¬£¬£¬²¢ÎªÈ«ÇòÏàÖúͬ°éÔÚºóÐøµÄÑо¿ÓëÓ¦ÓÃÀú³ÌÖУ¬£¬£¬ÌṩÒÔÇ°ÆÚÑз¢µ½ºóÆÚת»¯µÄÈ«Á÷³ÌÖ§³Ö¡£¡£¡£¡£

¡¡¡¡²Î¿¼ÎÄÏ×

¡¡¡¡1 WIRE, B. Capstan Therapeutics Announces Initiation of Phase 1 Trial of Lead In Vivo CAR-T Therapy, CPTX2309, for Treating Autoimmune Disease, <https://www.businesswire.com/news/home/20250611668181/en/Capstan-Therapeutics-Announces-Initiation-of-Phase-1-Trial-of-Lead-In-Vivo-CAR-T-Therapy-CPTX2309-for-Treating-Autoimmune-Disease> (2025).

¡¡¡¡2 AbbVie. AbbVie to Acquire Capstan Therapeutics, Further Strengthening Commitment to Transforming Patient Care in Immunology, <https://news.abbvie.com/2025-06-30-AbbVie-to-Acquire-Capstan-Therapeutics,-Further-Strengthening-Commitment-to-Transforming-Patient-Care-in-Immunology> (2025).

¡¡¡¡3 Gabizon, A. et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 54, 987-992 (1994).

Òªº¦´Ê£º

ÍƼöÐÂÎÅ

¡¾ÐµÃÀû´ÈÉÆ¡¿À´×Ô×ðɽµÄÀñÎï

2026-02-10

ϲ±¨ | ÁÉÄþеÃÀû¿Æ¼¼ÓÐÏÞ¹«Ë¾ÈëÑ¡ÁÉÄþʡר¾«ÌØÐÂÖÐСÆóÒµ

2026-01-30

·ÖÏíµ½

¡¾ÍøÕ¾µØͼ¡¿¡¾sitemap¡¿